Latest / Cult of Conspiracy / Deplorable Cult Nation: The Peptide Craze with Nurse Nicole
Transcript
- 0:01Speaker 1: Pull the curtain, name the lie, lie, lie. Bring the
- 0:11Speaker 1: buried truth to life. Welcome to the deplorable cult nation,
- 0:21Speaker 1: uncultured conspiracy. We dig beneath the polished story. Knowledge wraps
- 0:30Speaker 1: us up in armor. Stand around and see it clearly.
- 0:38Speaker 1: What the head won't say won't stay below.
- 0:43Speaker 2: We bring it up.
- 0:44Speaker 3: We let it show. Hi, and welcome back to another
- 0:58Speaker 3: episode of Deplorable Nation. I'm your host, Deplorable Janet. And today,
- 1:02Speaker 3: my beautiful darling co-host with the most, the beautiful, the talented,
- 1:09Speaker 3: the strong warrior, Nurse Nicole. How are you, my love?
- 1:14Speaker 2: I am fantastic. So glad to be here. We're going
- 1:17Speaker 2: to have a great topic to discuss tonight, something that's very,
- 1:20Speaker 2: very popular and on everybody's mind nowadays. But how are
- 1:24Speaker 2: you doing?
- 1:26Speaker 3: I am absolutely fantabulous, and I will say for the listeners,
- 1:32Speaker 3: strong opinions on this episode. You may or may not agree,
- 1:37Speaker 3: and that is completely okay, but here to give you
- 1:42Speaker 3: lots of important information, today we are going to be
- 1:46Speaker 3: talking about the peptide craze. Okay. Let me preface that
- 1:52Speaker 3: by saying this is not all about like GLP-1s. There
- 1:59Speaker 3: are some in here, but I already did a show
- 2:02Speaker 3: on that a long time ago. You can go check
- 2:04Speaker 3: out that episode. But for people who do not know
- 2:09Speaker 3: what a peptide is, there's a certain system in your body.
- 2:13Speaker 3: So amino acids are like the building blocks and they
- 2:19Speaker 3: form together. or bond together to form peptides and your
- 2:24Speaker 3: peptides then can form hormones. And then your hormones act
- 2:32Speaker 3: as a chemical messenger and they go to your receptors
- 2:37Speaker 3: and it locks it in on the cell. So what
- 2:39Speaker 3: that means is your amino acids make peptides, your peptides
- 2:44Speaker 3: will make hormones and your hormones will actually make Lock
- 2:50Speaker 3: in on the body's cells and tell your body what
- 2:53Speaker 3: it is supposed to be doing. That's why peptides are
- 2:59Speaker 3: an extremely relevant and popular topic these days. And anybody
- 3:07Speaker 3: that's on social media sees all over the place about peptides.
- 3:13Speaker 3: So what do you think, my dear?
- 3:17Speaker 2: I mean, I think it's a really complicated subject. This
- 3:20Speaker 2: is something that I really don't know enough about and
- 3:23Speaker 2: something that, um, I I'm glad you made the distinction
- 3:26Speaker 2: in the beginning because a lot of times people are
- 3:29Speaker 2: assuming it's just the GLP ones, which is another big
- 3:33Speaker 2: craze that everyone's going through. So, you know, I think
- 3:36Speaker 2: there is a lot of room to understand what a
- 3:40Speaker 2: peptide is. There's different versions of different peptides, but also, um,
- 3:45Speaker 2: you know, why is it that people are looking to
- 3:48Speaker 2: use peptides? You know, why is it such a big,
- 3:51Speaker 2: I wonder, and then also to like, you know, is
- 3:58Speaker 2: this something that once you start it, you have to
- 4:01Speaker 2: keep going, you know, or is this or is this
- 4:02Speaker 2: something that you can take, you know, the brakes on?
- 4:04Speaker 2: So I do have a lot of questions in this
- 4:08Speaker 2: as well, because I hear a lot about it. And
- 4:09Speaker 2: I know people can do different categories, different groups, there's
- 4:12Speaker 2: different types and, you know, trying to figure out the
- 4:15Speaker 2: right combination. And I'm like, I'm hoping these people are
- 4:18Speaker 2: being followed by somebody who's, who knows what they're doing
- 4:21Speaker 2: and like, where's the supply coming from and all of that,
- 4:23Speaker 2: which is a whole nother concern as well. But yeah,
- 4:27Speaker 2: I know it's definitely something that I feel like more
- 4:29Speaker 2: people are turning to nowadays. Just like the GLP ones.
- 4:33Speaker 1: Yeah.
- 4:34Speaker 2: Right.
- 4:35Speaker 3: So we have, they have discovered thousands of of peptides
- 4:42Speaker 3: in the human body that we make. And believe it
- 4:45Speaker 3: or not, you know, like we have the human genome. Well,
- 4:50Speaker 3: we also have a human peptidome. Who knew? I didn't
- 4:55Speaker 3: know anything about that. But they keep discovering new peptides
- 5:00Speaker 3: and adding to this and adding to this. And so
- 5:04Speaker 3: not only do they have to do with growth and
- 5:08Speaker 3: appetite and immunity, reproduction, sleep, pain, modulation, but these things
- 5:16Speaker 3: also depend on tissues, organs, your health status, and time.
- 5:23Speaker 3: And I will tell you, here's a little secret for you. Long,
- 5:29Speaker 3: long years and years ago, I did a story on
- 5:34Speaker 3: a doctor in Texas who discovered that people with cancer
- 5:43Speaker 3: don't have a certain type of peptide. And so he
- 5:49Speaker 3: isolated the peptide that healthy people have. And he started
- 5:54Speaker 3: treating cancers with this healthy person peptide. And he has
- 6:00Speaker 3: a hundred percent success rate. And people that were coming
- 6:07Speaker 3: in that had already done chemo radiation and you know,
- 6:11Speaker 3: had all the damage, especially that radiation does to people
- 6:16Speaker 3: and whatever. But he was treating people like that and
- 6:22Speaker 3: cancers that had like, you know, a very low survival
- 6:26Speaker 3: rate and things like that. And he actually cured these people.
- 6:31Speaker 3: So unfortunately, the Texas Medical Board swooped in several times,
- 6:39Speaker 3: put him in front of the board, tried to take
- 6:41Speaker 3: his license. The federal government, 17 different times, came after
- 6:48Speaker 3: this man. They broke in. They stole his research. They
- 6:52Speaker 3: sold it to a big pharma company. Big pharma tried
- 6:56Speaker 3: to replicate it, but they couldn't get it exactly right.
- 7:00Speaker 3: But they have tried and tried and tried and tried
- 7:02Speaker 3: to shut this man down because of his success rate.
- 7:06Speaker 3: So for me, something that simple, I'm impressed.
- 7:15Speaker 2: He knows something. He knows something they don't want him
- 7:18Speaker 2: to know.
- 7:19Speaker 3: A hundred percent.
- 7:21Speaker 2: Wow, wow, wow.
- 7:22Speaker 3: And so my whole thing with this is you have
- 7:27Speaker 3: the right to try whatever the heck you want to try. However,
- 7:32Speaker 3: the government, the FDA is like, We don't know enough
- 7:36Speaker 3: about these. So you shouldn't do it because pharma knows best.
- 7:44Speaker 3: Government knows best. The drugs are safe and effective. And peptides,
- 7:49Speaker 3: there's not enough research and whatever. And so they're dangerous
- 7:53Speaker 3: and people should stay away from them. However, that doesn't
- 7:57Speaker 3: mean that the FDA didn't bring some of these to market.
- 8:03Speaker 2: Right.
- 8:05Speaker 3: And then because of the things that they add to
- 8:09Speaker 3: these peptides or the way that they are synthesized, they
- 8:14Speaker 3: become highly dangerous. So we'll get into that a little
- 8:20Speaker 3: later with certain jumping on drugs, right?
- 8:24Speaker 2: Right.
- 8:26Speaker 3: And so here's an example or a couple examples of
- 8:29Speaker 3: some common human peptides that we produce in our body.
- 8:34Speaker 3: Did you know that insulin was one?
- 8:36Speaker 2: I did know that. I did know that one.
- 8:40Speaker 3: So for people who don't know, it regulates blood sugar, right? Oxytocin,
- 8:47Speaker 3: that's involved in labor contractions.
- 8:49Speaker 1: Right.
- 8:51Speaker 3: Milk ejection, aspects of social behavior. We have endorphins, which
- 8:58Speaker 3: are also peptides. They regulate pain and other nervous system function.
- 9:04Speaker 3: And then glucagon, which helps raise blood glucose when it
- 9:08Speaker 3: drops too low. So have they taken the glucagon peptide
- 9:18Speaker 3: over the years and put it into different formulations for
- 9:23Speaker 3: people to take pharmaceutical-wise? Why, yes. Yes, they have.
- 9:28Speaker 2: Convenient.
- 9:30Speaker 3: Isn't it? Also, defensins are another type of peptide that
- 9:35Speaker 3: we make, and these help the body defend against certain microbes.
- 9:41Speaker 2: Okay.
- 9:42Speaker 3: So.
- 9:44Speaker 2: Didn't know that one.
- 9:47Speaker 3: So peptides are for repair and recovery, weight loss, fat burning,
- 9:54Speaker 3: growth hormones, longevity, inflammatory treatment. antimicrobial, mood, anxiety, calming, stress, blah, blah, blah, neuroprotection,
- 10:09Speaker 3: and stroke recovery. So there's a wide range of things,
- 10:14Speaker 3: and especially if we have thousands in our body. I'm
- 10:17Speaker 3: sure there's a lot more than that.
- 10:19Speaker 2: Right.
- 10:20Speaker 3: There's a lot of cosmetics already that use peptides. Like
- 10:26Speaker 3: if anybody shops it, like Ulta, the Inky brand is
- 10:31Speaker 3: all contains peptides. Everything in it is peptides.
- 10:35Speaker 2: Okay.
- 10:37Speaker 3: And peptides and some of them have caffeine in them. Oh, well,
- 10:44Speaker 3: look at them fanciness.
- 10:46Speaker 2: Okay.
- 10:47Speaker 3: So wake me up before I go-go. I might need it.
- 10:53Speaker 3: So the FDA has approved ones. They have investigational ones.
- 11:01Speaker 3: They have compounded ones, research ones, the cosmetic ones, and
- 11:08Speaker 3: combinations and stacks. So there's all different kinds of categories
- 11:15Speaker 3: of these. And you're going to notice a theme because
- 11:20Speaker 3: we're going to talk about some of the peptides. I'm
- 11:25Speaker 3: so sorry that they're looking at. And the common theme
- 11:30Speaker 3: throughout is the FDA is like, oh, don't know if
- 11:34Speaker 3: it's safe. We don't have enough clinical information. Oh, animal studies,
- 11:38Speaker 3: just animal studies. And that's not good enough. So you're
- 11:44Speaker 3: going to see that theme throughout. But how do things
- 11:50Speaker 3: get pushed to market? Animal studies, right?
- 11:53Speaker 2: Right.
- 11:55Speaker 3: So it's okay for drugs and vaccines and things like that,
- 12:00Speaker 3: but it's not okay for peptides.
- 12:03Speaker 2: Hmm.
- 12:05Speaker 3: Isn't that sweet?
- 12:06Speaker 2: Isn't that interesting? Yes. Why, why, why?
- 12:11Speaker 3: Good questions. So one of the most heavily marketed and
- 12:18Speaker 3: widely used peptide, and this is not FDA approved, but
- 12:24Speaker 3: it's the BCP-157 or BPC-157, which is the healing peptide.
- 12:32Speaker 3: So this is supposed to help tendon injuries, ligament injuries, muscle, joint, intestines. Oh. Ulcers, inflammation,
- 12:44Speaker 3: wound healing, nerve recovery, and exercise recovery.
- 12:49Speaker 2: Wow.
- 12:50Speaker 3: So wide range of things that this particular peptide does.
- 12:55Speaker 3: And what BPC stands for is body protection compound. And
- 13:02Speaker 3: this is one that they usually use with multiple other
- 13:07Speaker 3: peptides in a combination stack to get more benefit. So
- 13:13Speaker 3: I will say I have a friend who did this.
- 13:17Speaker 3: She did a combo stack, but she got injured at
- 13:21Speaker 3: work severely. Hold on a minute. I've got a cough again. Allergies. Anyway,
- 13:33Speaker 3: she went through therapy and medication and surgeries and all
- 13:37Speaker 3: this stuff and nothing worked and she was still having
- 13:40Speaker 3: like decreased function in her arm and like massive pain
- 13:45Speaker 3: and stuff like that. She did this peptide stack and
- 13:50Speaker 3: within two weeks, everything was back to normal. Her functioning
- 13:56Speaker 3: was back to normal. She could lift her arm normal,
- 13:59Speaker 3: no pain, none of that stuff. So to me, that
- 14:07Speaker 3: deserves further investigation. warrant's concern which were some of these
- 14:15Speaker 3: that I picked out I'm like holy cow like if
- 14:20Speaker 3: these really do these things then.
- 14:24Speaker 2: Wonder why it's not FDA approved yet or.
- 14:26Speaker 3: It would go away wouldn't it so again everybody's like
- 14:34Speaker 3: oh well it's everybody that uses it says that it
- 14:38Speaker 3: works tremendously well However, the government's like, oh, my God,
- 14:44Speaker 3: animal studies and laboratory research. We need human controlled studies.
- 14:53Speaker 2: Right.
- 14:53Speaker 3: So they're like poo pooing on this, even though patients
- 14:56Speaker 3: have had remarkable results.
- 14:59Speaker 2: Hmm.
- 15:01Speaker 3: Now, if you have a peptide that naturally occurs in
- 15:04Speaker 3: your body. Wouldn't you rather try that than try medications?
- 15:10Speaker 2: Right. Well. Exactly. So why would they not turn to
- 15:14Speaker 2: versus a synthetic version of something else? Yeah. Why would
- 15:18Speaker 2: we want to do that?
- 15:19Speaker 3: A hundred percent. And so the FDA came in and
- 15:25Speaker 3: they're like, there isn't validated clinical protocol establishing that these
- 15:30Speaker 3: combinations are safer or more effective than individual ones. That's
- 15:37Speaker 3: just biohacking science said snarkily. It's not established medicine. That
- 15:43Speaker 3: came from their own papers. And I just want to say,
- 15:48Speaker 3: isn't medication the same? Because that's not established medicine. And
- 15:55Speaker 3: you're going to see through here that there are arguments
- 15:58Speaker 3: for why we shouldn't use peptides. But it also goes
- 16:07Speaker 3: along with medication. So it's okay for pharma-related stuff or whatever,
- 16:12Speaker 3: but it's not okay for peptides. So the arguments to
- 16:17Speaker 3: me are kind of BS, if you ask me.
- 16:21Speaker 2: Almost scripted to be that way. 100%.
- 16:26Speaker 3: So we have another one that's called TB500. This is
- 16:30Speaker 3: thymusin beta-4. This is another huge one that people use
- 16:36Speaker 3: in the injury recovery sector because tendon healing, ligament recover,
- 16:44Speaker 3: muscle joint wound healing, inflammation, athletic recovery, and tissue regeneration.
- 16:52Speaker 3: So this one is associated with thymazine beta-4, and that's
- 16:59Speaker 3: a naturally occurring peptide in your body that's involved in
- 17:03Speaker 3: cellular processes and tissue repair. So I could see why
- 17:11Speaker 3: this would be a super important thing. But their argument
- 17:17Speaker 3: is what happens when you manipulate tissue growth and blood
- 17:22Speaker 3: vessel growth pathways at the same time.
- 17:26Speaker 2: And how the system takes that in or how your
- 17:30Speaker 2: system adapts to it.
- 17:33Speaker 3: Now, if it has to do with blood vessel growth
- 17:36Speaker 3: and stuff, What did we just talk about on the
- 17:40Speaker 3: Botox episode with things rerouting, you know, tissues and blood
- 17:48Speaker 3: vessels and all of that stuff rerouting to try to
- 17:51Speaker 3: get around the toxin.
- 17:52Speaker 2: Right.
- 17:54Speaker 3: So it's okay for Botox, which is a neurotoxin and
- 17:58Speaker 3: that approval is okay, but we're questioning a peptide that
- 18:03Speaker 3: naturally happens in your body. So this one in particular,
- 18:09Speaker 3: I find highly interesting because it is on the WADA
- 18:20Speaker 3: prohibited list under growth factors and related substances. So that
- 18:26Speaker 3: means World Anti-Doping Agency. So athletes and stuff have been
- 18:32Speaker 3: using this and now they're testing them. for this because
- 18:37Speaker 3: it's a banned substance.
- 18:39Speaker 2: Interesting.
- 18:40Speaker 3: Because it's not FDA approved yet.
- 18:45Speaker 2: Right. And it's crazy because this is typically where I've
- 18:50Speaker 2: heard these peptides being used in that type of community.
- 18:55Speaker 2: I know a lot of people who weightlifting, bodybuilding, you know,
- 19:00Speaker 2: stuff like that. And so you're like, you know, it's like, okay, okay.
- 19:03Speaker 2: You know, but Where are they getting them from? How
- 19:06Speaker 2: are they using them? So, yeah, that's interesting that, again,
- 19:10Speaker 2: it's being labeled as such and then becoming a problem.
- 19:15Speaker 3: So there's another one that's CJC 1295. And this is
- 19:21Speaker 3: definitely a growth hormone all on its own. And so
- 19:29Speaker 3: this one, this one should personally be banned, in my opinion,
- 19:33Speaker 3: if they're going to ban anything, not the one that
- 19:35Speaker 3: we previously discussed. But this one increases muscle, improves recovery,
- 19:41Speaker 3: decreases body fat, improves sleep, improves skin and improves energy.
- 19:47Speaker 3: I'm not saying they should ban it. You know what
- 19:49Speaker 3: I'm saying? I'm just saying if you're going to ban
- 19:52Speaker 3: the other one that doesn't interfere with some of those things.
- 19:56Speaker 2: Exactly.
- 19:56Speaker 3: I'm curious. So this one is one of the more
- 20:03Speaker 3: common things that they use in these protein or peptide stacks,
- 20:08Speaker 3: the combinations that they do with all of these different things,
- 20:11Speaker 3: because it has so many benefits. So the government's like, nope,
- 20:17Speaker 3: it can cause swelling and joint discomfort and headaches and
- 20:23Speaker 3: changes in glucose and insulin resistance and increased heart rate
- 20:29Speaker 3: and blood pressure and worsening sleep apnea and abnormal tissue concerns.
- 20:39Speaker 3: And so the FDA specifically mentions on this particular peptide
- 20:45Speaker 3: increased heart rate and systemic vasodilation reactions, while also saying
- 20:54Speaker 3: that clinical data is very limited. Now, I want to
- 20:58Speaker 3: know if clinical data is very limited, How many people
- 21:03Speaker 3: were in it and where are they getting their information
- 21:06Speaker 3: from if there's very little clinical data?
- 21:10Speaker 2: Well, and that's just the thing, because when you say
- 21:13Speaker 2: you're stacking something, in my mind, that's more than one
- 21:17Speaker 2: thing being done.
- 21:18Speaker 1: Right.
- 21:18Speaker 3: 100%.
- 21:19Speaker 2: So what, yeah, like you said, what are they doing
- 21:23Speaker 2: to base the studies off of the general groups that
- 21:28Speaker 2: they're looking at and how long? I mean, as we've
- 21:30Speaker 2: talked about on previous shows all the time. that they
- 21:34Speaker 2: usually are poor studies because of the type of control group,
- 21:38Speaker 2: the people that are paying for the study. So it's
- 21:41Speaker 2: kind of interesting that these would be so popular, yet
- 21:45Speaker 2: they are not being approved by the three-letter agencies.
- 21:52Speaker 3: Unless there's big bucks in it for them.
- 21:54Speaker 2: Right, which every time we know they approve something, Pharma
- 21:57Speaker 2: gets their hands in it because now they can manipulate
- 21:59Speaker 2: it to their... Oh, 100%.
- 22:03Speaker 3: It's kind of like doing gain of function research, right?
- 22:07Speaker 3: To make things more virulent, more toxic and more damaging
- 22:13Speaker 3: and all the things. That is literally what pharma does
- 22:17Speaker 3: to medications. Like the government's been investigating things like cybicillin,
- 22:23Speaker 3: you know, mushroom use for PTSD and stuff like that.
- 22:28Speaker 3: let's get the government involved. Let's get big pharma involved.
- 22:32Speaker 3: So let's add all kinds of toxic ingredients and things
- 22:37Speaker 3: like that to it to manipulate it and make it
- 22:40Speaker 3: more damaging for your organs and all of that stuff
- 22:45Speaker 3: so we can add another patient.
- 22:47Speaker 2: Exactly. Because I feel like that when they started regulating
- 22:52Speaker 2: marijuana and stuff like that, there were people that were
- 22:56Speaker 2: complaining of not being able to tolerate certain substances that
- 23:00Speaker 2: were supposedly regulated by the government. And then it's like,
- 23:03Speaker 2: are they spraying the crops and different things that they're
- 23:06Speaker 2: using to dispense out to these people who are now
- 23:11Speaker 2: getting the supply that's being overseen by the government? Right. Yeah,
- 23:16Speaker 2: it's a real problem. And I know that Trump not
- 23:19Speaker 2: too long ago, I thought mentioned talking about the psychedelics
- 23:23Speaker 2: and some other stuff that they were looking at because
- 23:26Speaker 2: groups like veterans, you know, commonly are prescribed a lot
- 23:29Speaker 2: of opioids and psych medications and, you know, they were
- 23:33Speaker 2: looking at alternatives. So yeah, that's interesting. But the peptides,
- 23:38Speaker 2: I'm just so shocked because I feel like there's a
- 23:40Speaker 2: lot of people that are using them and But again,
- 23:44Speaker 2: I know there's a ton of different types. How they're
- 23:47Speaker 2: trying to not approve this stuff, it kind of makes
- 23:50Speaker 2: you wonder what's going.
- 23:50Speaker 3: On with that. Oh, 100%. So there's another one that's
- 23:56Speaker 3: in the same kind of group, and it's ipamoralin. Sorry
- 24:02Speaker 3: if I butcher the name on some of these because
- 24:04Speaker 3: they're extremely confusing. But that's another growth hormone. But here's
- 24:10Speaker 3: where the FDA has a problem. The FDA says that
- 24:16Speaker 3: this particular peptide can represent concerns with immunogenicity. And so
- 24:25Speaker 3: they're worried about you creating antibodies and whatever, because it's
- 24:30Speaker 3: a foreign substance that you're injecting. Okay. What about all
- 24:37Speaker 3: the fetal cells? Okay. bovine cells and swine cells and
- 24:44Speaker 3: all the other things that are in vaccinations and medications and,
- 24:49Speaker 3: you know, snake venom and certain medications and whatever. So
- 24:56Speaker 3: they're not concerned about that, but they're concerned about these
- 25:02Speaker 3: particular things. And so this particular peptide, they published a
- 25:08Speaker 3: study that, the FDA published a study involving IV for
- 25:16Speaker 3: gastric motility. And it said it reported serious adverse events,
- 25:21Speaker 3: including death. But on the same page, they also stated
- 25:28Speaker 3: that they don't have sufficient safety information. What?
- 25:34Speaker 2: Right. Okay. Okay. We know where that's going.
- 25:40Speaker 3: Whatever. So this one is a fat burning peptide. We
- 25:45Speaker 3: have AOD9604. And so this is another one people add
- 25:51Speaker 3: on to a stack. And here's the FDA's red flag.
- 25:58Speaker 3: It says that this particular peptide can present concerns, again,
- 26:05Speaker 3: regarding immunogenicity or aggregation which means that it could move
- 26:11Speaker 3: somewhere else excuse me don't pretty much every vaccine and
- 26:20Speaker 3: every medication move somewhere else yes.
- 26:23Speaker 2: Which people were told does not happen but we know
- 26:28Speaker 2: that's not.
- 26:28Speaker 3: True so again they're like oh this one could actually
- 26:33Speaker 3: cause you know problems and blah blah blah So we have...
- 26:40Speaker 3: Let's see.
- 26:42Speaker 2: Yeah.
- 26:43Speaker 3: This same peptide, they said they have serious adverse events
- 26:51Speaker 3: that have been identified that may be associated with this,
- 26:57Speaker 3: although causation is not quite clear.
- 27:00Speaker 2: So....
- 27:04Speaker 3: Again, where are you getting your data from? You can't
- 27:07Speaker 3: prove that it was from this, but you're going to
- 27:10Speaker 3: say stay away from it because we said so.
- 27:13Speaker 2: I don't know.
- 27:17Speaker 3: So here's your beauty peptide. It's a GHKCU. Okay. It's
- 27:26Speaker 3: naturally occurring copper binding peptide. So we make this in
- 27:31Speaker 3: our body. So this is associated with collagen production, skin remodeling,
- 27:37Speaker 3: wound healing, and inflammation. So this is one that they
- 27:42Speaker 3: use a lot in cosmetics and sunscreens and things like that.
- 27:48Speaker 3: Even though it's not FDA approved, it's still used. So, yeah.
- 27:58Speaker 3: This next one to me is interesting. It's called MOTS, M-O-T-S-C.
- 28:08Speaker 3: And this is a peptide associated with mitochondrial functioning and
- 28:13Speaker 3: metabolic regulation.
- 28:14Speaker 2: Oh, wow.
- 28:15Speaker 3: This one for me is huge.
- 28:18Speaker 2: That's big.
- 28:19Speaker 3: Huge, huge, huge. Mitochondria, your powerhouse, your cells, you need
- 28:24Speaker 3: it to function properly. And if they can do that
- 28:30Speaker 3: and regulate your metabolism, in the way it's supposed to be,
- 28:35Speaker 3: this one would be fantastic in my mind.
- 28:38Speaker 2: It'd be groundbreaking.
- 28:40Speaker 3: So this one improves insulin sensitivity, metabolic health, exercise performance,
- 28:47Speaker 3: fat loss, longevity, and mitochondrial functioning. That's a big list
- 28:53Speaker 3: of stuff. And so imagine if this really did work,
- 29:00Speaker 3: and pharma wasn't involved and the government wasn't involved, there
- 29:05Speaker 3: would be no more chronic patients. Correct. Because it would
- 29:09Speaker 3: fix your system. So the FDA, of course, swooped in
- 29:15Speaker 3: and they said, we don't have any human data exposure
- 29:21Speaker 3: for this. And so administration routes and things like that
- 29:26Speaker 3: lack safety information. So they're going to poo-poo this. until
- 29:31Speaker 3: later in the show.
- 29:35Speaker 2: Isn't it ironic that those that sell the panic try
- 29:40Speaker 2: to sell the cure but for this one we're trying
- 29:43Speaker 2: to calm down and possibly cure and they're like there's
- 29:48Speaker 2: no study so then why aren't they doing the studies
- 29:51Speaker 2: why aren't we putting money and effort into studies.
- 29:53Speaker 3: Because Because we already have patents for pharmaceutical medications. That
- 30:02Speaker 3: is why nobody is studying these things in depth because
- 30:06Speaker 3: pharmaceutical companies spend a hell of a lot of money
- 30:11Speaker 3: on patents and patent research and patent extension for evergreening patents.
- 30:18Speaker 3: And so it's big business for them. So why would
- 30:22Speaker 3: they want a competitive product? on the market and why
- 30:27Speaker 3: would they want people to have the option to choose
- 30:30Speaker 3: a peptide over a drug?
- 30:32Speaker 2: Good question. It is a great question.
- 30:37Speaker 3: So here's another one that I find fascinating. It's LL 37.
- 30:41Speaker 3: This is an antimicrobial peptide that we produce. And so
- 30:48Speaker 3: it's for infection. wound healing, inflammatory conditions, and immune modulation.
- 30:57Speaker 3: So imagine again, if we started using this instead of
- 31:04Speaker 3: antibiotics and stuff like that, we already make this peptide
- 31:07Speaker 3: in our body. So we would be no longer needing
- 31:12Speaker 3: antibiotics and stuff like that because it would treat whatever's
- 31:17Speaker 3: wrong with you.
- 31:18Speaker 2: You know, that one, as soon as you kind of
- 31:20Speaker 2: broke down what that one was capable of, I immediately
- 31:24Speaker 2: thought of our vaccine injured community would really, really benefit
- 31:30Speaker 2: from something like this, especially with the immune modulation. The
- 31:32Speaker 2: fact that it's like the wound, the inflammation and all that,
- 31:36Speaker 2: that would be huge. Maybe not a cure-all, but definitely
- 31:39Speaker 2: something that could help decrease the amount of the cytokine
- 31:43Speaker 2: storm with the spike protein and all that. So yeah,
- 31:46Speaker 2: wouldn't that be something? Yeah. Mm-hmm.
- 31:48Speaker 3: 100%. And that's why a lot of these that I'm
- 31:52Speaker 3: going to mention today are ones that I'm like, I
- 31:56Speaker 3: would try it. You know what I mean? That's a
- 31:59Speaker 3: big deal.
- 31:59Speaker 2: Yeah, if you're saying that, that's a big deal.
- 32:00Speaker 3: If I needed to try it, I would try it
- 32:02Speaker 3: because some of these are highly impressive, the properties that
- 32:07Speaker 3: they have. So with this LL37, the government, again, sweeps
- 32:15Speaker 3: in and it's like, oh, there's concerns surrounding this there's
- 32:19Speaker 3: not enough safety information and uh pre preclinical trials or
- 32:26Speaker 3: preclinical findings not even trials yeah i'm suggest potentially detrimental
- 32:32Speaker 3: reproductive effects and uh pro-tumorogenic effects which mean that spreads
- 32:39Speaker 3: tumors now let me ask you Did we do a
- 32:43Speaker 3: show not too long ago on a vaccination that affects
- 32:48Speaker 3: your reproductive system?
- 32:50Speaker 2: Yes, we did.
- 32:52Speaker 3: Yes, we did. So are there other drugs and stuff
- 32:58Speaker 3: on the market as well that mess with your reproductive system?
- 33:03Speaker 2: There's actually quite a bit.
- 33:05Speaker 3: Like COVID.
- 33:09Speaker 2: But not only that, how would they know that if
- 33:11Speaker 2: they didn't do the studies? 100%.
- 33:14Speaker 3: There's no trials.
- 33:16Speaker 2: Yeah. So how would we know that? We're just taking
- 33:18Speaker 2: a shot in the dark here. We're just taking a
- 33:19Speaker 2: little gamble. He said, she said. Is that how we
- 33:22Speaker 2: work with science?
- 33:23Speaker 1: Yes.
- 33:24Speaker 3: And that's how the government shuts this stuff down.
- 33:28Speaker 2: Right?
- 33:29Speaker 3: It tells you it's not safe and all that. Here's
- 33:32Speaker 3: another one that's amazing. It's called saline. And it is
- 33:38Speaker 3: a calming peptide. It's for anxiety, a cognitive enhancer, and
- 33:44Speaker 3: stress modulation compound. This has been researched. Russia has been
- 33:50Speaker 3: researching the next two that I'm going to talk about.
- 33:55Speaker 3: And so they have done lots of studies on this particular,
- 34:00Speaker 3: these two particular things. And so wouldn't that be amazing?
- 34:06Speaker 3: Because oh, I don't know, SSRIs would go away.
- 34:10Speaker 2: Yep, sure would. That's one of the most prescribed mental
- 34:17Speaker 2: health medications.
- 34:18Speaker 3: Yeah, that's- Anti-anxiety, depression, panic attacks, PTSD, all of these
- 34:27Speaker 3: things could benefit from this particular peptide. And the next one,
- 34:33Speaker 3: which is Samax, also Russian researched. It's for cognition, memory, focus, neuroprotection,
- 34:42Speaker 3: and stroke recovery. So holds a lot of promise for
- 34:48Speaker 3: a lot of different things. And of course, the government
- 34:52Speaker 3: comes in and it says, we don't care that Russia
- 34:56Speaker 3: looked at this and studied these. It's not FDA approved
- 35:00Speaker 3: for anxiety medication and it shouldn't be because it can
- 35:05Speaker 3: cause problems again with immunogenicity and aggregation. It could spread
- 35:12Speaker 3: other places. Well, don't SSRI spread other places?
- 35:16Speaker 2: Correct. They wreak havoc, wreak havoc on one's body. And
- 35:22Speaker 2: usually they are not just one that is prescribed, which
- 35:25Speaker 2: makes it even more of a problem because they, they
- 35:28Speaker 2: literally stack the medications and can cause more health issues
- 35:32Speaker 2: and then the patient can't really come off of them.
- 35:35Speaker 2: So yeah, it's weird that, you know, the peptide again
- 35:39Speaker 2: has the potential to have all these promising effects and
- 35:45Speaker 2: the emphasis is not there to try to get it
- 35:47Speaker 2: regulated for use.
- 35:50Speaker 3: Well, no. And with that particular peptide, that same X,
- 35:55Speaker 3: also Alzheimer's drugs would go away because it's, you know,
- 35:59Speaker 3: for cognition and memory and focus and all of that stuff.
- 36:03Speaker 3: And those are big business for them because, you know,
- 36:07Speaker 3: lower the cholesterol with cholesterol lowering drugs so that your
- 36:13Speaker 3: body doesn't have cholesterol to protect the brain. Then you
- 36:17Speaker 3: get focus problems. You get memory impairment. You get Alzheimer's.
- 36:22Speaker 3: You get all these dementia and all these things. And
- 36:26Speaker 3: so then we can sell you Alzheimer's drugs. But with this,
- 36:30Speaker 3: you wouldn't need it.
- 36:33Speaker 2: That's heartbreaking. You know, and this also increases the risk
- 36:36Speaker 2: of people going outside of normal instances of getting these
- 36:42Speaker 2: medications and can increase the risk of possibly getting contaminated or,
- 36:48Speaker 2: you know, inappropriate vials or peptides, whatever. You know, it's like, again,
- 36:55Speaker 2: these people maybe seeking treatment elsewhere and come in contact
- 36:58Speaker 2: with things that may not be as pure because we
- 37:01Speaker 2: don't have it here in the States where it's being
- 37:04Speaker 2: recognized as approved. So they may seek it elsewhere. And
- 37:08Speaker 2: that's usually where we get a lot of problems with
- 37:10Speaker 2: tainted goods, tainted medicines, you know?
- 37:13Speaker 3: So I'm glad you brought that up because that's going
- 37:16Speaker 3: to be a point that we're going to talk about
- 37:18Speaker 3: in a short bit. But it is with medications that
- 37:23Speaker 3: are actually FDA approved and put on the market. So
- 37:31Speaker 3: we have one called epitalon. It's another longevity one. And
- 37:37Speaker 3: so this one is for anti-aging, sleep, immune function, lifespan extension.
- 37:46Speaker 3: And so, and the government swoops in and they're like,
- 37:50Speaker 3: you can't make a leap from cell biology to animal
- 37:53Speaker 3: research to to theoretical mechanisms to human marketing. Isn't that
- 38:00Speaker 3: what all products that are put on the market by
- 38:03Speaker 3: the FDA? It literally is.
- 38:07Speaker 2: It literally is.
- 38:10Speaker 3: So their arguments on these are just absolutely retarded. So
- 38:15Speaker 3: this one is another one that I would be all
- 38:18Speaker 3: for or not that I'm not for. And I'll tell
- 38:23Speaker 3: you why. So this one is PT-141 or Brevolanotide. This
- 38:30Speaker 3: one is FDA approved. And listen to what this is
- 38:34Speaker 3: approved for. Generalized hypoactive sexual disorder in premenopausal women.
- 38:48Speaker 2: Of course it is.
- 38:51Speaker 3: Now I just want to say Don't your hormones fluctuate
- 38:56Speaker 3: with different life stages?
- 38:58Speaker 2: They do. They do.
- 39:00Speaker 3: And is it common for your hormones to drop when
- 39:06Speaker 3: you're premenopausal?
- 39:08Speaker 2: A hundred percent. That's part of the problem, but we're, yeah,
- 39:14Speaker 2: that's exactly what, and that's a normal process.
- 39:16Speaker 3: We're marketing this drug to treat people for a normal life.
- 39:23Speaker 3: life stage occurrence.
- 39:25Speaker 2: Correct.
- 39:27Speaker 3: And then they're like, but guess what?
- 39:30Speaker 2: What?
- 39:31Speaker 3: Nausea, flushing, injection site reactions, headache, transient increased blood pressure,
- 39:37Speaker 3: decreased heart rate and hyperpigmentation of your skin amongst hundreds
- 39:43Speaker 3: of other side effects. Those are some of the things
- 39:47Speaker 3: that are listed as common. side effects for people who
- 39:51Speaker 3: are taking this FDA approved drug to treat something that
- 39:55Speaker 3: they don't need.
- 39:57Speaker 2: So we can't look into the things that are going
- 39:59Speaker 2: to help longevity and, you know, balance out the inflammation and,
- 40:04Speaker 2: you know, possibly help maybe the hormones just take a natural,
- 40:08Speaker 2: more natural process in the correction process. We're just going
- 40:11Speaker 2: to go in and target the female side. you know,
- 40:16Speaker 2: cycle of life and try to disrupt it with some
- 40:19Speaker 2: more synthetic stuff. Okay. Okay.
- 40:22Speaker 3: A hundred percent. So here's another one that's FDA approved
- 40:27Speaker 3: and the use for this is stupid. This is a,
- 40:32Speaker 3: another thing that stimulates growth hormone. I remember growth hormones bad. Right.
- 40:37Speaker 3: And the other ones we discussed this growth hormone good.
- 40:41Speaker 3: So it's FDA approved. for reducing excess abdominal fat in
- 40:48Speaker 3: adults with HIV-associated lipodystrophy. How big of a percentage of
- 40:59Speaker 3: population is that? You have to have an adult and
- 41:04Speaker 3: with HIV and a problem with your lipids.
- 41:09Speaker 1: Hmm.
- 41:11Speaker 3: Now, before, didn't they say that they're worried about any
- 41:16Speaker 3: kind of growth hormones because it could affect your insulin resistance, etc., etc.?
- 41:24Speaker 3: What's it going to do to your lipids? Well, this
- 41:27Speaker 3: one is okay. The other ones are not. And I'm
- 41:34Speaker 3: not sure how they pick and choose which ones are
- 41:38Speaker 3: good and which ones are not good.
- 41:39Speaker 2: Because....
- 41:42Speaker 3: It causes glucose intolerance and carries diabetes risk and hypersensitivity
- 41:50Speaker 3: to this because of the shit they put in it.
- 41:55Speaker 3: Injection reactions, muscle and joint pain, swelling, and an increase
- 42:03Speaker 3: in your growth hormone factors. So, hmm. But this one's okay.
- 42:12Speaker 3: safe and effective, people don't worry.
- 42:15Speaker 2: I wonder if they think or they know something we don't.
- 42:22Speaker 2: Is this coming down the pipeline? I don't know. Why
- 42:25Speaker 2: would they emphasize such a.
- 42:28Speaker 3: Specific That particular approval group was very strange to me
- 42:33Speaker 3: and I'm like so what and it made me think
- 42:39Speaker 3: if it's HIV associated And we have found SV40 in
- 42:48Speaker 3: a lot of stuff.
- 42:50Speaker 2: Yes, we have.
- 42:51Speaker 3: Lately, would that not be an indicator of why this
- 42:57Speaker 3: suddenly got approved?
- 42:59Speaker 2: I mean, yeah. Because we all know cancer, turbo cancer,
- 43:04Speaker 2: all of those things are on the rise.
- 43:08Speaker 3: Yeah.
- 43:09Speaker 2: No, for sure. Again.
- 43:10Speaker 3: And like Dan said, the COVID markers and the HIV
- 43:15Speaker 3: markers are identical.
- 43:18Speaker 2: Yes. Yes. That's something that a lot of people are
- 43:22Speaker 2: not understanding. They're getting very confused about that. And, and,
- 43:27Speaker 2: and I think it's important, you know, to mention that
- 43:30Speaker 2: it has to do with your immune system and the
- 43:32Speaker 2: way those labs look on paper, you know, just to
- 43:35Speaker 2: elaborate what some of these patients look like with their labs,
- 43:39Speaker 2: when it comes to their HIV status and their immune system,
- 43:42Speaker 2: is the same as what we're seeing in those who
- 43:44Speaker 2: have had these types of cancers or, you know, possibly
- 43:48Speaker 2: from the SV40 and the induced from the COVID-19 vaccine. So, yeah.
- 43:53Speaker 2: And to know that there could be a product like
- 43:57Speaker 2: that to target that is quite, quite interesting.
- 44:03Speaker 3: When I ran across that one, I was like, Oh,
- 44:07Speaker 3: it made me scratch my head and go, what the,
- 44:11Speaker 3: there's something behind that. So here's another FDA approved lovely diddy,
- 44:19Speaker 3: which has problems. The next two do. So semaglutide, which
- 44:24Speaker 3: is a GLP-1, ozimbic, wagovi, and ribelsis are all in
- 44:32Speaker 3: this category. And they're like, well, you can't use the
- 44:38Speaker 3: body protection compound or the MOTC. because there's not enough
- 44:44Speaker 3: clinical study, this has, semaglutide has way more clinical research.
- 44:52Speaker 3: And I'm just going to ask this question. Does clinical
- 44:56Speaker 3: research mean that the product is safer? No.
- 45:02Speaker 2: We know that.
- 45:04Speaker 3: I'm just saying, that's their reasoning of why they can't
- 45:08Speaker 3: approve these other two. Because they're like, oh, no, there's
- 45:13Speaker 3: not enough clinical research, and this is the only one
- 45:17Speaker 3: that's approved because this is safer. Okay. If the government
- 45:25Speaker 3: says it's safe, it must be safe. So, of course,
- 45:30Speaker 3: we know. What are some of the side effects from
- 45:33Speaker 3: these JLP1s?
- 45:36Speaker 2: Well, some of the common ones that we're seeing are
- 45:38Speaker 2: muscle wasting, eyesight problems, gastric dumping. I have some coworkers
- 45:44Speaker 2: that mysteriously ended up needing their gallbladders removed emergently. you know,
- 45:50Speaker 2: issues with eating, right? They're sometimes they're constantly nauseous, constantly having,
- 45:56Speaker 2: you know, diarrhea, they can't really eat or drink too
- 45:59Speaker 2: much without having like that dumping syndrome. So I mean, it's,
- 46:03Speaker 2: it's pretty intense. And I know a lot of people
- 46:05Speaker 2: will argue that. And I could say that there's people
- 46:09Speaker 2: that get these types of medications, like off the market,
- 46:13Speaker 2: You can buy these things online, you know, and not
- 46:16Speaker 2: be followed by a doctor. So are those the people
- 46:19Speaker 2: that are probably more high risk for those serious issues? Yes.
- 46:22Speaker 2: But even under physicians care, we know a lot of
- 46:25Speaker 2: people that take these. And, you know, even on a maintenance,
- 46:30Speaker 2: if you skip any kind of. um, regimen, they become
- 46:35Speaker 2: violently ill, um, and have a really hard time getting
- 46:39Speaker 2: themselves back on a board. And so a lot of
- 46:43Speaker 2: times they're not able to eat and drink and keep
- 46:44Speaker 2: things down. And to me, that is not worth it
- 46:47Speaker 2: to me to have a snatched waistline when I can't
- 46:50Speaker 2: eat or drink and keep anything down. And now I'm
- 46:52Speaker 2: getting weaker and losing my, I mean, I know I'm So, yeah,
- 47:00Speaker 2: there's just to say there's a lot of things with
- 47:02Speaker 2: the GLP ones and a lot of lawsuits that have
- 47:04Speaker 2: come forward because people are now realizing. And I even
- 47:09Speaker 2: think if I'm wrong, there was some infertility issues because,
- 47:14Speaker 2: you know, there really were pushing GLP ones for me.
- 47:16Speaker 2: They wanted to push it on me for metabolic syndrome,
- 47:20Speaker 2: assuming that I had some of these general characteristics there.
- 47:23Speaker 2: And without even skipping a beat, they were trying to
- 47:25Speaker 2: put me on them a couple of years ago. And
- 47:27Speaker 2: I was like, I'm not really feeling that. But they
- 47:30Speaker 2: were trying to say that, oh, it can help PCOS. And,
- 47:33Speaker 2: you know, if you want to get pregnant and all
- 47:35Speaker 2: this other stuff. But now I'm hearing that there may.
- 47:37Speaker 3: Be some fertility issues. Again, it's affecting fertility, which was
- 47:43Speaker 3: their thing about why they couldn't approve this peptide for use.
- 47:47Speaker 3: Because it could affect fertility, even though there's no studies
- 47:52Speaker 3: on it. Okay.
- 47:54Speaker 2: Yeah.
- 47:56Speaker 3: So the FDA reported 990 adverse events reported associated with
- 48:00Speaker 3: semaglutide as of May 31st of 2026. But I want
- 48:03Speaker 3: to remind ladies and gents that That that is only
- 48:16Speaker 3: what is logged into VAERS.
- 48:19Speaker 2: VAERS, correct.
- 48:20Speaker 3: Because VAERS is complicated. It's time consuming. It's very long.
- 48:26Speaker 3: If you have a doctor's office that prescribed this for
- 48:30Speaker 3: you and they're on electronic systems, you have patients every
- 48:34Speaker 3: five to 10 minutes, you do not have the time
- 48:38Speaker 3: to sit down and fill out a VAERS report.
- 48:42Speaker 2: Correct. They make it purposely like that. And that's one
- 48:47Speaker 2: of the things that RFK Jr. was talking about, possibly
- 48:50Speaker 2: revisiting and trying to make the system better, a little
- 48:53Speaker 2: bit more user friendly. Because even, again, during the pandemic,
- 48:57Speaker 2: when all that stuff was happening with the COVID-19 vaccine,
- 49:00Speaker 2: I mean, they were stripping licenses from people and threatening them.
- 49:04Speaker 2: who were providers who were filling out VAERS to report
- 49:07Speaker 2: because we're mandated reporters to say, hey, there's a possible
- 49:11Speaker 2: issue here. And so, yeah, VAERS is severely underreported. That's
- 49:16Speaker 2: very well known that it's underreported. And it's because of
- 49:18Speaker 2: the things you just said. All the reasons is too
- 49:21Speaker 2: time consuming, not user friendly, et cetera, et cetera, et cetera.
- 49:24Speaker 2: And as a nurse to be on shift and have like,
- 49:28Speaker 2: there's just no way.
- 49:29Speaker 3: And you're trying to take care of all these other patients.
- 49:32Speaker 3: You mean you don't have four hours to sit down
- 49:34Speaker 3: and fill out a VAERS report on one patient?
- 49:37Speaker 2: We don't. And I will tell you, there's been times
- 49:39Speaker 2: where people have come at us saying that we were
- 49:41Speaker 2: part of the problem for not doing it. But it's like,
- 49:44Speaker 2: just like you said, it is literally like a full-time job.
- 49:48Speaker 2: You would have to sit there and to do it
- 49:50Speaker 2: accurately and give it the justice that it deserves to
- 49:53Speaker 2: make sure that it's completely done right.
- 49:55Speaker 3: You would need a dedicated staff specifically for it.
- 50:00Speaker 2: And I'm sure they would have they would have all
- 50:02Speaker 2: the time to full time, because it's not just, you know,
- 50:06Speaker 2: one vaccine, it's any type of vaccine that there may
- 50:08Speaker 2: be some questions on. And there's other programs as well,
- 50:13Speaker 2: like the what is it called the CICP, there's other programs, again,
- 50:19Speaker 2: that people can report things to if they feel as
- 50:21Speaker 2: if a medication is is causing a potential problem. So
- 50:25Speaker 2: I'm wondering if this would fall under that subject or
- 50:27Speaker 2: are they counting it as a type of injection for
- 50:30Speaker 2: that for VAERS? I'm not sure what these would be considered,
- 50:34Speaker 2: but it should be reported if there's a problem, if
- 50:37Speaker 2: you're experiencing all these issues, because sometimes they say report
- 50:40Speaker 2: it to the company. Well, I don't know if I
- 50:43Speaker 2: have a good faith in that, that they would do
- 50:45Speaker 2: the right thing if you're reporting it.
- 50:47Speaker 3: They'd open the mail and they would laugh and they
- 50:50Speaker 3: would throw it in the trash immediately or the shredder.
- 50:54Speaker 2: Literally.
- 50:56Speaker 3: So the next one is also one of the GLP
- 51:01Speaker 3: ones that's already approved. And this is Terzura peptide and
- 51:06Speaker 3: this is Manjaro and Zepbound. Zepbound is the newer one.
- 51:12Speaker 3: So for marketed for type two diabetes, obesity or weight
- 51:17Speaker 3: management and obstructive sleep apnea in appropriate patients. I'm going
- 51:23Speaker 3: to say my dad is very elderly because I'm old.
- 51:29Speaker 3: I'm senior menu old. My dad is very old and
- 51:35Speaker 3: he has diabetes, but he's very skinny. He's very frail.
- 51:42Speaker 3: And unbeknownst to me, because I'm in a totally different state,
- 51:47Speaker 3: they put him on Monjaro. And he dropped weight so rapidly.
- 51:54Speaker 3: He looks literally like a skeleton with skin over it.
- 52:01Speaker 3: And when I found out, I'm like, what in the hell?
- 52:04Speaker 3: Get off of that. stuff because that is that is
- 52:09Speaker 3: insane to me i i don't know why you would
- 52:12Speaker 3: take somebody that's already really skinny and put them on
- 52:16Speaker 3: this medication knowing that it does this so whatever.
- 52:20Speaker 2: Their organs i mean like that's that can't be good
- 52:23Speaker 2: for your organs either as we see people having problems yeah.
- 52:27Speaker 3: Not at all and so it has the same kind
- 52:30Speaker 3: of side effects as the semi-glutide does So that one
- 52:35Speaker 3: has 730 adverse events reported as of May the 30th. Again,
- 52:45Speaker 3: you're going to have to report that in a system.
- 52:47Speaker 3: I've never reported in anything other than VAERS. Right. But
- 52:51Speaker 3: I'm assuming they're all very complicated systems because why would
- 52:55Speaker 3: they make them easy? Because it would make the drug
- 52:59Speaker 3: companies look bad if there was a lot of products.
- 53:02Speaker 2: They don't want people to Right. You know, we want
- 53:06Speaker 2: to look good on paper. We want everybody to think
- 53:09Speaker 2: that everything is safe and effective, just like you're told.
- 53:12Speaker 2: Don't question it. It's all good. Meanwhile, everybody's lining their pockets.
- 53:16Speaker 2: And then again, as we've said on previous shows. The people,
- 53:20Speaker 2: the community, they are the control group. At this point,
- 53:23Speaker 2: you are the study because how many things is the
- 53:25Speaker 2: FDA approved just to turn around in a few years
- 53:28Speaker 2: or decades? Oh, just kidding. We found that it does X, Y,
- 53:32Speaker 2: and Z. And meanwhile, it wasn't really safe.
- 53:35Speaker 3: Or like we talked about with the mRNA flu thing,
- 53:39Speaker 3: they knew there were issues, but they approved it anyway.
- 53:43Speaker 3: So what the hell difference does it make if they're...
- 53:48Speaker 3: you know, using you as a lab rat, why can't
- 53:51Speaker 3: you try a peptide instead? I don't, it's the same, right?
- 53:57Speaker 3: It's still investigational. So here's another one. And the FDA
- 54:02Speaker 3: is pissed about this one. Um, it's called red, a
- 54:06Speaker 3: true tide and it's the marketed as the next big
- 54:09Speaker 3: weight loss peptide. Um, this one is getting enormous attention,
- 54:15Speaker 3: especially from the government. Because this one is a triple agonist.
- 54:20Speaker 3: So it's GLP-1, GIP, and glucagon all together, all three.
- 54:29Speaker 3: So this is being investigated for obesity and metabolic disease.
- 54:35Speaker 3: The FDA will not approve it. They explicitly state that
- 54:41Speaker 3: this cannot be used in compounding under federal law. And
- 54:48Speaker 3: has not been found safe and effective for any condition
- 54:53Speaker 3: at all. So.
- 54:56Speaker 2: We know where this is going.
- 54:59Speaker 3: If it does all three. And my opinion is anytime
- 55:04Speaker 3: the FDA says something, I believe the total opposite. If,
- 55:09Speaker 3: because glucagon is one of the natural peptides. So is GLP-1.
- 55:14Speaker 3: So is GIP-1. those are naturally occurring peptides in your body.
- 55:22Speaker 3: So my thinking is this one is too effective with
- 55:28Speaker 3: fewer side effects. And that's probably why they're like, Oh,
- 55:33Speaker 3: it's federal law. You can't use this medication. That's the
- 55:37Speaker 3: first thing that popped into my head.
- 55:39Speaker 2: You're probably right at this point. We know that if
- 55:42Speaker 2: they say it's just the worst thing for you, It
- 55:45Speaker 2: probably is not. They're just trying to make it so
- 55:48Speaker 2: that it's not widely available or used until they can
- 55:52Speaker 2: find something else to pin it on and then, you know,
- 55:55Speaker 2: release the fracking.
- 55:58Speaker 3: Yeah, and this is crazy. So they have found counterfeit,
- 56:03Speaker 3: and this is what I alluded to earlier, counterfeit semaglutide
- 56:10Speaker 3: and that terzapeptide On the market, at eight times the
- 56:19Speaker 3: concentration of the approved medication, which can lead to severe vomiting,
- 56:28Speaker 3: esophageal tears, like all kinds of stuff. And so, hello,
- 56:34Speaker 3: they're doing it with medications that are already FDA approved.
- 56:40Speaker 3: And it made me think... Remember on one of the
- 56:45Speaker 3: shows before we talked about, or you had mentioned the
- 56:49Speaker 3: MMR vaccine and the overfilling issue.
- 56:52Speaker 2: Oh yeah. Not knowing. Yeah.
- 56:55Speaker 3: So I'm wondering if this isn't another one of those
- 56:58Speaker 3: things where they're like, well, after a while, this peptide
- 57:02Speaker 3: breaks down. And so we have to add more to
- 57:05Speaker 3: it so that when they do the testing, it actually
- 57:08Speaker 3: shows that it's fine. Or are they just knowingly? putting
- 57:15Speaker 3: way too much stuff in something which wouldn't be the
- 57:18Speaker 3: first time in our history that that's happened.
- 57:21Speaker 2: Not to mention the amount of fakes and things that
- 57:25Speaker 2: get put in it as well, or trying to duplicate
- 57:28Speaker 2: it and it not be the correct thing. I think
- 57:31Speaker 2: that's another big issue we're probably seeing with these peptides
- 57:35Speaker 2: and GLP-1s as well. You can literally get some of
- 57:38Speaker 2: these from anywhere.
- 57:41Speaker 3: Well, and here's another one that the FBI... I almost
- 57:45Speaker 3: said FBI, that the FDA said cannot be used legally.
- 57:52Speaker 3: It's illegal here to do this. It's cagrelinatide and it's
- 57:58Speaker 3: another weight loss peptide. Same thing where they're like, oh no,
- 58:03Speaker 3: that one's illegal. You can't use that for any reason whatsoever.
- 58:07Speaker 3: And I'm thinking, I don't know. why they would be like, well,
- 58:14Speaker 3: these aren't legal at all. These are illegal.
- 58:17Speaker 2: Like downright illegal, like not even like black box warning
- 58:22Speaker 2: or like what they're just like, you can't no touchy.
- 58:25Speaker 3: Right.
- 58:26Speaker 2: Hmm.
- 58:27Speaker 3: So questionable to me. So those are some of the
- 58:30Speaker 3: ones that I wanted to go over. Cause I was like,
- 58:33Speaker 3: these are very interesting. Um, and, and like I said,
- 58:36Speaker 3: we wouldn't have time to do the thousands of them show, but,
- 58:41Speaker 3: it's up to people what they think, you know, of
- 58:44Speaker 3: whether you're for peptides, you're against peptides, or you're wanting
- 58:49Speaker 3: to find out more information.
- 58:52Speaker 2: I mean, at first, I'll be the first. A good
- 58:54Speaker 2: friend of mine who listens to us, she's probably going
- 58:57Speaker 2: to laugh because she'd be like, Nicole is totally against.
- 59:00Speaker 2: But it's because I don't, I just don't trust it.
- 59:03Speaker 2: I don't know enough about it, but it doesn't help
- 59:06Speaker 2: that the government, the FDA, they're not willing to do
- 59:10Speaker 2: more research into it. So I find that kind of odd.
- 59:12Speaker 2: But then of course, hearing some of the things that
- 59:14Speaker 2: we talked about in the podcast, Um, it doesn't surprise
- 59:18Speaker 2: me now that that's probably all intentional, um, from the government. But,
- 59:23Speaker 2: you know, one of the things that I know, um,
- 59:25Speaker 2: has been a huge issue and something that, you know,
- 59:28Speaker 2: I hope people that listen to this, um, cause obviously
- 59:31Speaker 2: Janet did an amazing job and I didn't really contribute
- 59:34Speaker 2: too much to this cause you, you know, you just
- 59:36Speaker 2: held it down, but is how easy it is to
- 59:39Speaker 2: get a hold of these products and how the federal government, um,
- 59:44Speaker 2: really needs to kind of regulate where these things come from.
- 59:47Speaker 2: Because I think we've even had situations where these are
- 59:51Speaker 2: being put in vials that are said to be a
- 59:54Speaker 2: peptide or something like that. And it's potentially laced with
- 59:57Speaker 2: something far nefarious. So just be very careful where you
- 1:00:01Speaker 2: get your medicines from. I know sometimes in the States,
- 1:00:05Speaker 2: it can be more expensive. These are not cheap. I
- 1:00:09Speaker 2: know my friend's husband is spending hundreds of dollars a
- 1:00:13Speaker 2: month to be on these peptides. He stacks them. He
- 1:00:17Speaker 2: does some other stuff. He said he's never felt better.
- 1:00:19Speaker 2: He's like a totally different person. And I can speak
- 1:00:22Speaker 2: to that as well. So they do have some really
- 1:00:26Speaker 2: great things about them, but you also know that people
- 1:00:30Speaker 2: sometimes can't afford that. And so they're seeking out other
- 1:00:32Speaker 2: areas to get it. And there's been a huge, I
- 1:00:36Speaker 2: actually received a petition to sign that they want to
- 1:00:39Speaker 2: present to our federal government to say, Hey, like we
- 1:00:42Speaker 2: really have to be careful where these are coming from.
- 1:00:44Speaker 2: We have to make sure that we're at least looking
- 1:00:47Speaker 2: at what's in these vials because people are getting things
- 1:00:49Speaker 2: that are tainted, contaminated, and they're thinking it's one thing
- 1:00:53Speaker 2: and it's really another. So I don't know how I
- 1:00:54Speaker 2: want to go about that. And it's, it's literally specific
- 1:00:56Speaker 2: to peptides. I don't know. Do you have any thoughts
- 1:00:58Speaker 2: on that? Like, like would, would for them to be, well,
- 1:01:01Speaker 2: obviously it's regulation, but then that's the government again, getting involved,
- 1:01:05Speaker 2: but I don't know, you know, for safety.
- 1:01:07Speaker 3: And you know, one thing that it made me think
- 1:01:09Speaker 3: about was like drugs, like generic drugs. Because we buy
- 1:01:18Speaker 3: almost all of our generic drugs from China.
- 1:01:23Speaker 2: You're right.
- 1:01:24Speaker 3: Okay. And so the way that the regulations go, you
- 1:01:32Speaker 3: only are required to have 20% Of the required element,
- 1:01:41Speaker 3: like the whatever you're going for. And the medication and
- 1:01:45Speaker 3: the others, 80% is just whatever you want to put
- 1:01:51Speaker 3: in it. That's why patients that are on generic drugs,
- 1:01:55Speaker 3: there's so many different manufacturers for the same generic medication.
- 1:02:01Speaker 3: They're always a different color. They're always a different shape.
- 1:02:04Speaker 3: They're always a different size. It's because they don't have
- 1:02:08Speaker 3: the same compounds in them. And so the government willingly
- 1:02:14Speaker 3: purchases all of these medications from China, knowing that they're
- 1:02:21Speaker 3: not up to standards, that they're tainted in a lot
- 1:02:25Speaker 3: of aspects. And we also buy a lot of our
- 1:02:29Speaker 3: food additives and things that are grass or beauty stuff.
- 1:02:36Speaker 3: From China as well, or from other places that are questionable.
- 1:02:41Speaker 3: And so if you're leaving it up to the government
- 1:02:45Speaker 3: to regulate, we know how great they regulate grass standards
- 1:02:52Speaker 3: and food additives and additives for, you know, products and
- 1:02:59Speaker 3: stuff like that. So would I want them to be
- 1:03:02Speaker 3: into federal regulation? I'm not sure.
- 1:03:04Speaker 2: I agree. it's kind of hard because again, there's a
- 1:03:08Speaker 2: lot of people that, I mean, even as patients that
- 1:03:10Speaker 2: I've cared for, they get medicine, their medicines from Mexico, Canada,
- 1:03:14Speaker 2: but they try to for a cheaper option. And, you know,
- 1:03:18Speaker 2: it's a big deal. They're not regulated here. And, you know,
- 1:03:21Speaker 2: you don't know what you're actually getting in it. So
- 1:03:23Speaker 2: I don't, I don't know. But do you.
- 1:03:25Speaker 3: Really know what you're getting here? Exactly. You know, like
- 1:03:31Speaker 3: a lot of people, even with vaccines are still in
- 1:03:34Speaker 3: the dark to, you know, you have your ingredient list
- 1:03:38Speaker 3: and then you have an excipient list, which means these
- 1:03:42Speaker 3: are additional add-ons to the vaccination that are also included
- 1:03:47Speaker 3: in that, you know, that contain like heavy metals and antibiotics.
- 1:03:52Speaker 3: And that's where you get fetal cells and all of
- 1:03:55Speaker 3: that stuff. And, you know, all the things, right. And
- 1:04:00Speaker 3: so my thing is, who is going to regulate it
- 1:04:04Speaker 3: because even if the fda regulate it you know like
- 1:04:08Speaker 3: the grass standards and stuff they're like oh we're too
- 1:04:11Speaker 3: busy we don't have staff there's not enough people we'll
- 1:04:15Speaker 3: never look at it so these are always going to
- 1:04:17Speaker 3: be okay for eternity because there's no one raising a
- 1:04:22Speaker 3: flag going this is a problem.
- 1:04:24Speaker 2: They're not yeah they're not pushing it so yeah that's Yeah.
- 1:04:29Speaker 2: So basically, to that point is, you know, there may
- 1:04:32Speaker 2: be some really great things about these peptides. But as
- 1:04:35Speaker 2: you've heard, the really good ones seem to not be
- 1:04:38Speaker 2: supported by the government. FDA approved, if you will. And
- 1:04:42Speaker 2: so just make sure that you are very clear on
- 1:04:45Speaker 2: where you're getting your supply from and that you really
- 1:04:47Speaker 2: are being followed by somebody who is a licensed profession
- 1:04:51Speaker 2: who knows what to look for, because obviously this can
- 1:04:54Speaker 2: really affect you. Right.
- 1:04:55Speaker 1: Absolutely.
- 1:04:56Speaker 2: In a lot of ways.
- 1:04:56Speaker 3: Because you're messing with normal human biology. Exactly. In any case. Okay.
- 1:05:03Speaker 3: So whether they're good or bad, you're still having to
- 1:05:10Speaker 3: inject them, use them topically, take them, which we'll go
- 1:05:14Speaker 3: over all that in a minute. But, you know, there's
- 1:05:18Speaker 3: still that opportunity for your body to be like.
- 1:05:23Speaker 2: Right.
- 1:05:23Speaker 3: Rejecting. something and building antibodies toward it.
- 1:05:28Speaker 2: And how, is there an antidote to peptides? Like if
- 1:05:31Speaker 2: you take one and you have a horrible reaction, I
- 1:05:33Speaker 2: guess it's just SOL until it comes out of your system. Right.
- 1:05:36Speaker 2: I mean, how would that work? I don't even know.
- 1:05:38Speaker 3: That's a good question. And, and again, there's no, there's
- 1:05:42Speaker 3: no research that I'm aware of out there that, that
- 1:05:46Speaker 3: looks at these things long-term and it's like, okay, well,
- 1:05:51Speaker 3: you know, five years down the road, we're, we're seeing
- 1:05:54Speaker 3: this or we're not seeing this or whatever. And if
- 1:05:57Speaker 3: something arises, how do we treat it? It's like we
- 1:06:01Speaker 3: make all of these problems for ourself by medications and
- 1:06:06Speaker 3: vaccines and stuff. And then we're like, oh crap, we
- 1:06:09Speaker 3: don't know how to treat these things because we've never
- 1:06:12Speaker 3: seen it before. We've never encountered it before what we're causing.
- 1:06:17Speaker 2: Sounds like the vaccine injured in the long haul.
- 1:06:20Speaker 3: 100%.
- 1:06:22Speaker 2: Yeah, we don't know how to find a cure, even
- 1:06:26Speaker 2: though we told you it was safe. And now we
- 1:06:28Speaker 2: don't know what to do. Yeah, so it goes in
- 1:06:29Speaker 2: line with what we continue to see in today's age. Right.
- 1:06:35Speaker 3: So the FDA, of course, has problems with stacking these combos,
- 1:06:40Speaker 3: you know, adding multiple ones together. And they're like, we
- 1:06:44Speaker 3: don't have any clinical trials available. evaluating most of the
- 1:06:48Speaker 3: combinations together. Well, no shit because they don't want to
- 1:06:51Speaker 3: spend the money to look at it and neither does
- 1:06:53Speaker 3: pharma unless it benefits them. And so they're like, well,
- 1:07:00Speaker 3: this is a bad idea. You should never stack peptides
- 1:07:03Speaker 3: together because that could cause all these problems and then
- 1:07:08Speaker 3: we can't isolate which one it's coming from. Let me
- 1:07:12Speaker 3: ask you a question, folks. You've heard me say this
- 1:07:14Speaker 3: a hundred million times. But that's just like vaccines, right?
- 1:07:20Speaker 3: We have multivax injections where you have, you know, DTaP, iPole, MMR, blah, blah, Hib,
- 1:07:29Speaker 3: all these things combined into one vaccine. That's not been studied.
- 1:07:35Speaker 3: Or you have an infant and they come in and
- 1:07:39Speaker 3: you're giving them four vaccines at a time. Same thing.
- 1:07:43Speaker 3: You don't know. Or how about this? This is one
- 1:07:47Speaker 3: of my favorites. You get the mental health cocktail, right?
- 1:07:51Speaker 3: And so they can't just put you on one medication.
- 1:07:55Speaker 3: They have to put you on multiple at a time.
- 1:07:57Speaker 3: You have to be on uppers. You have to be
- 1:07:59Speaker 3: on downers. You have to be on, you know, all
- 1:08:01Speaker 3: these things at once. And then you have all these
- 1:08:05Speaker 3: symptoms that are competing with each other and your body's
- 1:08:09Speaker 3: in a state of frenzy. So why are peptides any different?
- 1:08:15Speaker 3: than medications or vaccinations. They're not.
- 1:08:20Speaker 2: They're not. And the problem that we constantly bring out
- 1:08:24Speaker 2: that I think people need to understand because they come
- 1:08:26Speaker 2: and say anti-science, anti-vax, which some people may be. I
- 1:08:30Speaker 2: can't speak for everybody, but it's holding a standard. It's
- 1:08:33Speaker 2: holding the government to a standard that to say that
- 1:08:36Speaker 2: you keep saying these things are safe and effective in
- 1:08:40Speaker 2: conjunction with one another, but you have not a single
- 1:08:43Speaker 2: study to back it. Yeah. And it's just like, that's
- 1:08:47Speaker 2: why people don't trust you. And so, but to your point,
- 1:08:51Speaker 2: because that's not happened, you know, why would they say
- 1:08:54Speaker 2: that they can't do it with this? So again, it's
- 1:08:56Speaker 2: just typical, you know, um confusion i.
- 1:09:01Speaker 3: Do that's why it makes no sense to me like
- 1:09:05Speaker 3: any of their arguments on these things it's like well
- 1:09:09Speaker 3: don't don't stack because it's not safe because we don't
- 1:09:12Speaker 3: know what these combinations will do well you also don't
- 1:09:17Speaker 3: know about the combinations of vaccinations or medications that you
- 1:09:22Speaker 3: literally approved and put on the market.
- 1:09:25Speaker 2: It's performative outrage on their part it's like we already
- 1:09:29Speaker 2: know you're full of shit very correct but okay you
- 1:09:33Speaker 2: know it's like fine so.
- 1:09:36Speaker 3: Here's another thing that um when you if you go
- 1:09:39Speaker 3: to a clinic and you get peptides um a lot
- 1:09:44Speaker 3: of times they will suggest the stacks but they'll also
- 1:09:48Speaker 3: suggest other things to take along with it. So supplementation.
- 1:09:54Speaker 3: So vitamins are going to be huge. They're going to
- 1:09:57Speaker 3: push lots of different vitamins and electrolytes and, you know,
- 1:10:01Speaker 3: collagen and protein and vitamin D and magnesium and all
- 1:10:06Speaker 3: of these things. They're going to tell you, take all
- 1:10:08Speaker 3: these things and take amino acids, which hello, you need
- 1:10:13Speaker 3: amino acids anyway, before you make peptides. And so, This
- 1:10:19Speaker 3: is big business for them too. And I want people
- 1:10:22Speaker 3: to understand this because most places where you go clinic
- 1:10:27Speaker 3: wise to get these injections of peptides or these pills
- 1:10:32Speaker 3: or whatever form you're taking, they also conveniently have our
- 1:10:39Speaker 3: brand supplements here. You should take these. And then they'll
- 1:10:45Speaker 3: try to sell you a multivitamin and they'll try to
- 1:10:48Speaker 3: sell you, you know, vitamin D or magnesium or whatever,
- 1:10:52Speaker 3: all these things separately. It's a money racket is what
- 1:10:57Speaker 3: that is. Should you need some of these things? Possibly
- 1:11:03Speaker 3: because we're all different. However, you should be getting a
- 1:11:06Speaker 3: lot of these things naturally occurring in your body and
- 1:11:10Speaker 3: through your diet anyway. And if you have sun outside,
- 1:11:15Speaker 3: there's your vitamin D. It's a better source than the pill.
- 1:11:20Speaker 2: And I think this is just another way for them
- 1:11:22Speaker 2: to make money, right? I mean, at this point, that's
- 1:11:24Speaker 2: part of the package, the whole, you know, appeal to it. Yeah.
- 1:11:30Speaker 2: So it's again, interesting. Okay.
- 1:11:33Speaker 3: So you brought up the quality issues earlier and that
- 1:11:39Speaker 3: is a concern, but Same, like I said, with medications
- 1:11:42Speaker 3: and products and anything. It's a concern. But that kind
- 1:11:47Speaker 3: of stuff literally happens all the time. That's why we
- 1:11:50Speaker 3: have the recall and removal list from the FDA themselves
- 1:11:54Speaker 3: for products that they approved. And then later they're like, oh, well,
- 1:12:00Speaker 3: all of this stuff had glass in it. We should
- 1:12:03Speaker 3: probably remove that from the market. You know what I'm saying?
- 1:12:07Speaker 3: Just got to be smart about stuff. So here's some
- 1:12:13Speaker 3: interesting things. There's a big difference between a peptide being
- 1:12:20Speaker 3: natural and it being safe, especially if it is biomanipulated
- 1:12:26Speaker 3: by big pharma and the government. I would be very
- 1:12:30Speaker 3: wary in question. Your body producing a molecule naturally does
- 1:12:38Speaker 3: not mean that injecting a manufactured version is safe. Because,
- 1:12:45Speaker 3: as we talked about before, when you take things that
- 1:12:48Speaker 3: are biosynthesized or synthetic of any kind, it can shut
- 1:12:55Speaker 3: off your body's own ability to produce. Hence, birth control, hormones, steroids,
- 1:13:02Speaker 3: all of that kind of stuff. So those are concerns
- 1:13:06Speaker 3: for me. It's definitely concerns that I have. But they're also,
- 1:13:13Speaker 3: their arguments are, well, the amount that you get in
- 1:13:16Speaker 3: one of these peptides might be higher than what your
- 1:13:18Speaker 3: body normally has or produces. It might remain active for
- 1:13:24Speaker 3: longer than the natural version. Soda drugs. That's why their arguments,
- 1:13:30Speaker 3: I'm like... you know what, you're talking out both sides
- 1:13:34Speaker 3: of your mouth. Injecting it may send it into tissues
- 1:13:40Speaker 3: or in the bloodstream in places they don't intend. Again,
- 1:13:49Speaker 3: I just have to say, the body may recognize and
- 1:13:53Speaker 3: manufacture peptide And then develop antibodies. Same with any kind
- 1:14:00Speaker 3: of medication. Blah, blah, blah, blah, blah, blah. So here's
- 1:14:06Speaker 3: the news that I said about the MOTC and the
- 1:14:12Speaker 3: BPC one. This is current as of October 19th of 2026.
- 1:14:18Speaker 3: Hot off the press. Significant regulatory story unfolding as we speak.
- 1:14:29Speaker 3: Reuters actually reported that the FDA and the Department of
- 1:14:34Speaker 3: Health and Human Services had submitted proposed interim policies to
- 1:14:40Speaker 3: the White House that could ease restrictions on compounding certain
- 1:14:47Speaker 3: popular peptides. And then also in July of this year,
- 1:14:53Speaker 3: the advisory committee with the FDA recommended easing restrictions for
- 1:14:59Speaker 3: several peptides, including the BPC, the TB500, and the MOTC.
- 1:15:06Speaker 3: So several of the ones that I said I thought
- 1:15:10Speaker 3: were going to be very beneficial. The government has an
- 1:15:15Speaker 3: approval panel now working on trying to ease restrictions on those.
- 1:15:22Speaker 2: Let's see how that goes.
- 1:15:26Speaker 3: So they're recommended for possible inclusion on a compounding list.
- 1:15:32Speaker 3: And so I want people to know compounding takes place
- 1:15:36Speaker 3: all the time. There are certain compounding pharmacies that if
- 1:15:42Speaker 3: you need certain ointments or certain uh elixirs liquids whatever
- 1:15:49Speaker 3: these compounding pharmacies will actually mix these products together um
- 1:15:56Speaker 3: per you know applicable compounding rules uh so this is
- 1:16:02Speaker 3: not new that happens all the time so they're working
- 1:16:06Speaker 3: on these more popular ones um and so uh we did,
- 1:16:14Speaker 3: we discussed a while ago, the, uh, peptide purity problem.
- 1:16:19Speaker 3: It can be a thing. Uh, what's actually in the vial, uh,
- 1:16:24Speaker 3: label alone cannot establish what's actually in the vial. Somebody
- 1:16:28Speaker 3: actually has to look at it. Um, but this is
- 1:16:34Speaker 3: the same as, you know, like when we did the
- 1:16:37Speaker 3: micro needling show and I said, Sarah Nova on their
- 1:16:41Speaker 3: own website has different ingredient listing for their product. This
- 1:16:49Speaker 3: could be a problem with these as well because we
- 1:16:55Speaker 3: don't know is the substance that it's supposed to be
- 1:16:58Speaker 3: actually what's in there. What's the potency of it? I
- 1:17:02Speaker 3: don't know. Do peptides have a potency? I don't know.
- 1:17:06Speaker 3: Are they studying that? What is an acceptable amount of
- 1:17:11Speaker 3: potency for certain peptides? We don't know. they don't know
- 1:17:16Speaker 3: about medications either. Is it sterile? Was the process at
- 1:17:22Speaker 3: the manufacturing place sterile? Does it contain any bacteria? Medications
- 1:17:28Speaker 3: do all the time, hence the FDA removal process. Does
- 1:17:33Speaker 3: it degrade over time? Hence the MMR overfilling stuff. And
- 1:17:39Speaker 3: are there things in there that are not supposed to
- 1:17:42Speaker 3: be like glass, metal, Stuff like that. So certificate of
- 1:17:48Speaker 3: analysis can be super duper useful, but it depends on
- 1:17:53Speaker 3: who performed the testing, what methods were used, and whether
- 1:17:58Speaker 3: the report actually applies to the batch that's being sold.
- 1:18:03Speaker 3: Kind of like the different batches on the COVID.
- 1:18:08Speaker 2: Exactly. Continuing to just prove once more that it's one
- 1:18:14Speaker 2: sided and how they're looking at the study or like
- 1:18:19Speaker 2: you want to move forward with it. Oh boy.
- 1:18:22Speaker 1: Yeah.
- 1:18:23Speaker 2: That's rough. Because again, we don't know. And a lot
- 1:18:26Speaker 2: of people are using these and they're taking them without
- 1:18:30Speaker 2: necessarily somebody monitoring them so it's like how do you
- 1:18:34Speaker 2: know how potent it is how much it is you
- 1:18:37Speaker 2: know some people give a very small dose some people
- 1:18:39Speaker 2: do more i mean you can really make yourself sick
- 1:18:42Speaker 2: on these so it's very interesting I don't know. That's
- 1:18:46Speaker 2: just crazy.
- 1:18:47Speaker 3: Absolutely crazy. So you can do oral, topical, intranasal, or
- 1:18:53Speaker 3: injectable on most of these peptides. And the FDA approves
- 1:18:58Speaker 3: certain routes for certain ones of these peptides that we
- 1:19:02Speaker 3: discussed today. And so what are the long-term risks? We
- 1:19:08Speaker 3: don't know. So we can only do what's known or observed,
- 1:19:13Speaker 3: how we see or what people tell us. Plausible biological
- 1:19:19Speaker 3: concerns because they're not studying them. So is it possible
- 1:19:22Speaker 3: something's going to happen? And unknown long-term risk because we
- 1:19:27Speaker 3: don't know. And so here's the thing. Peptides that influence
- 1:19:33Speaker 3: growth hormones are raised questions about glucose metabolism and tissue growth.
- 1:19:39Speaker 3: peptides involved in blood vessel formation raise questions about those
- 1:19:43Speaker 3: pathways and different conditions that arise and like I said
- 1:19:49Speaker 3: earlier the Botox thing is the perfect example of again
- 1:19:55Speaker 3: do as I say not as I do it's not
- 1:19:58Speaker 3: okay for this but it's okay for that because Botox
- 1:20:02Speaker 3: is a multi-billion dollar industry so here's a we're gonna
- 1:20:07Speaker 3: I'm gonna rush through this because I know we've way
- 1:20:09Speaker 3: over time. Um, but they're like animal studies can be misleading. Okay.
- 1:20:19Speaker 3: Whether the same biological mechanism operates in humans, whether the
- 1:20:23Speaker 3: compound reaches the relevant tissue, whether ineffective or safe human
- 1:20:28Speaker 3: dose exist, ding, ding, ding, whether the result holds up
- 1:20:33Speaker 3: in controlled human risk trials and, um, With that, I'm
- 1:20:38Speaker 3: going to say, what about the trials they can't do
- 1:20:41Speaker 3: because of ethics? Because like we've talked about on many,
- 1:20:45Speaker 3: many shows, there's no studies or clinical data to back
- 1:20:50Speaker 3: up certain things because they can't test children or infants
- 1:20:54Speaker 3: or pregnant women or cancer patients or et cetera, et cetera.
- 1:21:00Speaker 3: So those are all concerns. And so... the hormones, fertility,
- 1:21:07Speaker 3: and the reproductive health. Some peptides actually influence the hypothalamus,
- 1:21:14Speaker 3: pituitary gland, or reproductive organs. And so they can, you know,
- 1:21:23Speaker 3: they're supposed to regulate sex hormones, ovulation, sperm production, stuff
- 1:21:27Speaker 3: like that. But again, HPV vaccine and other medications and
- 1:21:36Speaker 3: vaccinations that affect the same way or the same systems,
- 1:21:42Speaker 3: they're approved. So, I don't know. And then they're like,
- 1:21:50Speaker 3: we gotta look for financial incentives behind this and we're
- 1:21:56Speaker 3: highly concerned because these, the peptide clinics or the telehealth
- 1:22:01Speaker 3: or doctors or compounding pharmacies, online sellers or influencers or
- 1:22:07Speaker 3: small businesses, this could be a problem because they're out
- 1:22:10Speaker 3: to make money. Isn't Big Pharma?
- 1:22:16Speaker 2: I'm like, so what's your point? Because so is Big Pharma.
- 1:22:18Speaker 2: And they're nailing that with the billions and billions and
- 1:22:21Speaker 2: billions of dollars a year just on some of their,
- 1:22:25Speaker 2: just like on one product.
- 1:22:26Speaker 3: So they specifically name all the places.
- 1:22:30Speaker 2: Yeah.
- 1:22:31Speaker 3: That would be giving these peptide things. And they're like,
- 1:22:34Speaker 3: you're not allowed to make money. Only the government and
- 1:22:38Speaker 3: big pharma are allowed to make money. I find that humorous.
- 1:22:42Speaker 3: So I don't know. So I don't know. A lot
- 1:22:46Speaker 3: of times they're like, it's a placebo effect. They don't work.
- 1:22:53Speaker 3: People want to feel better. So they do feel better.
- 1:22:56Speaker 3: It's not really the peptides. Um, like you mentioned earlier,
- 1:23:00Speaker 3: what happens when something goes wrong? That's a question, but
- 1:23:04Speaker 3: that's also a question again with medications, vaccinations, procedures, who
- 1:23:10Speaker 3: do you have that knows what they're doing that can
- 1:23:12Speaker 3: actually treat? And are you set up to treat someone? Um,
- 1:23:17Speaker 3: and the big question for me is informed consent. Um,
- 1:23:22Speaker 3: I would want to know what I was getting, where
- 1:23:24Speaker 3: it was coming from, but I, I, we'll be honest
- 1:23:28Speaker 3: with you. I would feel more comfortable with a informed
- 1:23:32Speaker 3: consent on a peptide than I would on a medication
- 1:23:36Speaker 3: that has a hundred ingredients in it for vaccination. I'm
- 1:23:41Speaker 3: just saying.
- 1:23:42Speaker 2: A hundred percent. And that's really how it could be, right?
- 1:23:45Speaker 2: We want to be as natural, right. As holistic as possible,
- 1:23:52Speaker 2: try to exhaust those avenues. And then if something doesn't happen,
- 1:23:57Speaker 2: then maybe talk about, you know, a different alternative maybe,
- 1:24:00Speaker 2: but yeah, this, I mean, pharma pharma has never cured
- 1:24:05Speaker 2: one disease. So let's be real.
- 1:24:08Speaker 3: And that's why, like for me, you know, I was
- 1:24:11Speaker 3: kind of concerned at first about peptides and whatever. And
- 1:24:15Speaker 3: when I My friend's like, oh, I'm doing that. And
- 1:24:19Speaker 3: like two weeks, all my stuff was gone. And I
- 1:24:21Speaker 3: was like, oh, good for you. But I'm thinking like,
- 1:24:26Speaker 3: are we going to have any effects down the road
- 1:24:28Speaker 3: or anything? But if I had the choice after doing
- 1:24:34Speaker 3: all this investigation between pharma beds and peptides, I think
- 1:24:40Speaker 3: I'd go the peptide route.
- 1:24:42Speaker 2: Yeah. I mean, definitely there's a, there's a plus to
- 1:24:45Speaker 2: this if we can get them to, you know, not
- 1:24:49Speaker 2: taint the source. So yeah, no, definitely it's, it's, I
- 1:24:55Speaker 2: guess why people are so drawn to them because they
- 1:24:58Speaker 2: do seem to have, you know.
- 1:25:00Speaker 3: And they're not tainted by pharma at the moment. A
- 1:25:04Speaker 3: lot of things are not. Now the ones that are,
- 1:25:07Speaker 3: I would stay very far away from.
- 1:25:09Speaker 2: I just would. Well, even for what they're used for,
- 1:25:14Speaker 2: it's kind of a little bit much, you know?
- 1:25:17Speaker 1: Yeah.
- 1:25:19Speaker 3: So I don't know, but I hope people learn something
- 1:25:24Speaker 3: from this episode. I learned a lot when I was
- 1:25:27Speaker 3: looking this stuff up because.
- 1:25:28Speaker 2: I'm like, what? Yeah, it's very complex. I mean, that's
- 1:25:31Speaker 2: the thing. Yeah, it is. You have to know what
- 1:25:35Speaker 2: you're looking at. And I remember when people started talking
- 1:25:38Speaker 2: about peptides and again, most of the ones that I
- 1:25:42Speaker 2: knew about were people that were in like weightlifting, bodybuilding,
- 1:25:46Speaker 2: wanting to like be fit. And I was like, how
- 1:25:49Speaker 2: is that going to help? But, and like the combination,
- 1:25:54Speaker 2: how do you know what's the good combination? And, you know,
- 1:25:57Speaker 2: it takes a little bit of trial and error, but
- 1:25:59Speaker 2: then also to like, I have a friend who's on
- 1:26:02Speaker 2: it and they are, their labs are quite exceptional. And
- 1:26:05Speaker 2: some of them are way beyond the optimal range on
- 1:26:08Speaker 2: certain things. And I'm like, are you being monitored? You know,
- 1:26:11Speaker 2: cardiac wise, like are there things that are also being
- 1:26:14Speaker 2: looked at to make sure that you're safe? Cause you
- 1:26:16Speaker 2: may be improving in some areas, but could it be
- 1:26:19Speaker 2: too much on those vital organs overload, you know? And I, I've,
- 1:26:25Speaker 2: I wasn't getting that vibe from them. It wasn't like
- 1:26:28Speaker 2: it was being monitored. It was just like, Oh, we
- 1:26:30Speaker 2: have to come in and get like basic blood work.
- 1:26:32Speaker 2: But I'm like, what about other testing just to make
- 1:26:35Speaker 2: sure your vital organs are okay. So, you know, just
- 1:26:38Speaker 2: a thought to that as well, but definitely an interesting subject.
- 1:26:43Speaker 3: If they put somebody on one of the GLP ones
- 1:26:46Speaker 3: that's approved. Are they having those patients come in and
- 1:26:51Speaker 3: are they monitoring them for renal failure and liver disease?
- 1:26:56Speaker 3: And are they checking their heart or their pancreas or
- 1:26:59Speaker 3: their gallbladder? Are they drawing the labs that are necessary
- 1:27:04Speaker 3: to check on those things?
- 1:27:05Speaker 2: They're supposed to, you would think, right? You would think
- 1:27:08Speaker 2: that when it has such a systemic issue or systemic response,
- 1:27:13Speaker 2: excuse me, within your body, how many things is affected
- 1:27:16Speaker 2: that you would have that. And that would be part
- 1:27:19Speaker 2: of your maintenance to follow up. But I mean, as
- 1:27:22Speaker 2: we're seeing, no, probably not because people are having all
- 1:27:26Speaker 2: these problems, these health issues, the eye issues, the muscle wasting,
- 1:27:29Speaker 2: the gastric dumping. Clearly they're not being followed enough to
- 1:27:33Speaker 2: be like, this is a problem.
- 1:27:35Speaker 3: So providers are like, prescribe, thrive. So I'll prescribe it
- 1:27:41Speaker 3: and you go thrive on your own. Like, don't bother me.
- 1:27:44Speaker 2: Right.
- 1:27:45Speaker 3: My whole thing with like the GLP ones, I'm not judging.
- 1:27:49Speaker 3: Anybody does that, that's your business. But my thinking personally is,
- 1:27:55Speaker 3: why do you need a medication that changes your body
- 1:27:58Speaker 3: makeup to have you lose weight when you can make
- 1:28:02Speaker 3: changes faster? to your diet or to your daily routine,
- 1:28:06Speaker 3: add walking, you know, whatever, do chair yoga, whatever things
- 1:28:10Speaker 3: that will help. But we're, we're, we're a spoiled, lazy,
- 1:28:16Speaker 3: entitled society and we want everything fixed overnight. So that's
- 1:28:23Speaker 3: why the question of these peptides is kind of a
- 1:28:27Speaker 3: toss up, up in the air. Cause I can see
- 1:28:30Speaker 3: pros and cons on both sides. So, That's kind of
- 1:28:34Speaker 3: where my stance is on this.
- 1:28:36Speaker 2: I agree. No, I agree.
- 1:28:37Speaker 3: But it's your right to try if you want to
- 1:28:39Speaker 3: try it. and it works for you god bless i'm
- 1:28:44Speaker 3: so happy You know what I mean?
- 1:28:45Speaker 2: Well, that's what I'm saying. Like, you know, there should
- 1:28:48Speaker 2: be the opportunity, but it also should be done in
- 1:28:53Speaker 2: a manner that you are as safe as possible. And
- 1:28:56Speaker 2: there is some sort of follow-up or maintenance to make
- 1:28:59Speaker 2: sure that it's not causing more harm because again, A
- 1:29:03Speaker 2: lot of these people get to the point where they
- 1:29:05Speaker 2: can't come off of it or they don't want to
- 1:29:06Speaker 2: come off of it because they start going back to it.
- 1:29:08Speaker 2: And so it's like, you know, like you said, there's
- 1:29:12Speaker 2: even with some of the good changes, there's not lifestyle changes.
- 1:29:16Speaker 2: And so people just assume, oh, the injection is fine
- 1:29:19Speaker 2: and this is what I can have for the rest
- 1:29:21Speaker 2: of my, you know, and it's like at some point
- 1:29:24Speaker 2: they may not be good for you long term. Over time,
- 1:29:27Speaker 2: there may be some issues or things you really need
- 1:29:30Speaker 2: to be careful on so that we know you're safe
- 1:29:33Speaker 2: and your organs are safe and all the other things.
- 1:29:34Speaker 2: And so hopefully, yeah, that's something that people are at
- 1:29:38Speaker 2: least taking into consideration, having that conversation with their doctor,
- 1:29:42Speaker 2: making sure that they're being open about things to just
- 1:29:45Speaker 2: be proactive versus reactive. Because unfortunately, GLP-1s, They're reactive. These
- 1:29:50Speaker 2: patients have permanent damage. I mean, there's like no going back.
- 1:29:55Speaker 2: So for a lot of people, this is really bad.
- 1:29:57Speaker 3: Well, and, and with those as well, it's become a problem.
- 1:30:02Speaker 3: If you stop that, you have rapid rebound fat gain.
- 1:30:08Speaker 3: It is like, it is like compounded and so, so, so,
- 1:30:13Speaker 3: so quickly. And your weight is going to be way
- 1:30:17Speaker 3: higher than what you were when you started it in
- 1:30:20Speaker 3: the first place and at a rapid pace. So how
- 1:30:26Speaker 3: unhealthy is it for you to gain weight that rapidly? Correct.
- 1:30:30Speaker 2: Well, same as to lose weight that rapidly. Like you said,
- 1:30:33Speaker 2: that's a shock to the system. People are not understanding
- 1:30:37Speaker 2: that when you lose that kind of weight that quickly,
- 1:30:39Speaker 2: your organs are going to be affected. That's a shock
- 1:30:41Speaker 2: for us. So, yeah, rapid weight gain, rapid weight loss.
- 1:30:46Speaker 2: I mean, they are they can be just as dangerous. So, yeah,
- 1:30:48Speaker 2: like you said, it's it's concerning and people only see
- 1:30:51Speaker 2: like that scale number or how they look. But we
- 1:30:54Speaker 2: all know these people who are on these because they
- 1:30:57Speaker 2: have a look to them.
- 1:30:59Speaker 3: Right.
- 1:30:59Speaker 2: Yeah. Yeah, I would call Theo's wimpy face. So, you know,
- 1:31:04Speaker 2: it's just, yeah, who wouldn't want to lose a few pounds?
- 1:31:07Speaker 2: But I'm not injecting myself with that stuff.
- 1:31:10Speaker 3: Yeah, no.
- 1:31:11Speaker 2: I'll be thicker than a snicker until then.
- 1:31:13Speaker 3: Hey, thicker is not a bad thing. You know what
- 1:31:20Speaker 3: I mean?
- 1:31:20Speaker 1: Yeah.
- 1:31:21Speaker 2: Curvy is good.
- 1:31:24Speaker 3: Skeletal is bad. Oh, you're right.
- 1:31:26Speaker 2: Yeah, we don't want that either. So....
- 1:31:31Speaker 3: Thank you so much for joining me for another episode.
- 1:31:34Speaker 3: You are amazing. I love you so much. You're always
- 1:31:37Speaker 3: such a wonderful, beautiful light in this world. I really
- 1:31:42Speaker 3: thank you for being my fabulous co-host.
- 1:31:48Speaker 2: I love you asking me. I'm actually really honored. I don't.
- 1:31:51Speaker 2: I don't know if I've ever told you that, but
- 1:31:53Speaker 2: I mean, you could ask anybody and you asked me,
- 1:31:55Speaker 2: so I'm very grateful to it. I don't take it lightly.
- 1:31:57Speaker 2: I think you do a phenomenal job. I mean, everybody
- 1:32:00Speaker 2: who listens knows the amount of research. I mean, you
- 1:32:03Speaker 2: can hear it. There's a lot of information behind it,
- 1:32:06Speaker 2: a lot of time, a lot of effort. And so
- 1:32:08Speaker 2: I hope people really see that and understand that there's
- 1:32:12Speaker 2: a lot of good information that she spends time on
- 1:32:15Speaker 2: making sure that you guys have the most and most
- 1:32:18Speaker 2: up to date, like best information to do these shows.
- 1:32:21Speaker 2: Cause it is a privilege, you know, to be able
- 1:32:22Speaker 2: to educate and raise awareness. So I'm very grateful as well.
- 1:32:26Speaker 2: Very grateful.
- 1:32:27Speaker 3: And I like it too, because I get to learn
- 1:32:31Speaker 3: as I go. If it's something I don't know about,
- 1:32:33Speaker 3: I'm like, Holy moly.
- 1:32:35Speaker 2: Right.
- 1:32:36Speaker 3: And I love learning something new. So, you know, it's
- 1:32:39Speaker 3: an opportunity for me as well. But listeners, if you
- 1:32:43Speaker 3: have suggestions, I got one, I got two actually from
- 1:32:48Speaker 3: a person the other day that was like, do you
- 1:32:50Speaker 3: ever take suggestions for sews?
- 1:32:52Speaker 2: Yes.
- 1:32:53Speaker 3: Absolutely. Because there are so many health topics and medical
- 1:32:58Speaker 3: topics out there that need to be covered and covered
- 1:33:04Speaker 3: in a way that, you know, people can understand and
- 1:33:07Speaker 3: that helps them um so yeah feel free to send
- 1:33:11Speaker 3: those those.
- 1:33:12Speaker 2: Where do you so where do you usually have people
- 1:33:14Speaker 2: send them just dm you.
- 1:33:15Speaker 3: Uh yeah they can they can message me on instagram
- 1:33:19Speaker 3: or you know x i always say twitter i know
- 1:33:24Speaker 3: x twitter whatever it is whatever the new word the
- 1:33:26Speaker 3: lingo is lock it so where can the wonderful ladies
- 1:33:35Speaker 3: and gents find you at my friend Yes.
- 1:33:38Speaker 2: So I am a previous Friday Q & A nurse
- 1:33:42Speaker 2: on the Nurses Report. We've actually branched out, although our
- 1:33:45Speaker 2: episodes are still on there. So we are now the
- 1:33:48Speaker 2: Sternerub Podcast. We've been doing podcasts for a couple of years,
- 1:33:52Speaker 2: but we're now going to be our own, the Sternerub
- 1:33:55Speaker 2: Podcast on Spotify and on Rumble. And then I also
- 1:34:00Speaker 2: co-host on the Frontline Messengers Podcast with Dan the Messenger,
- 1:34:04Speaker 2: who is my brother in Christ. Of course, I'm here
- 1:34:08Speaker 2: with you, Miss Janet, to do the medical shows. And
- 1:34:11Speaker 2: then also active on X at Hennessy, H-E-N-N-A-C-0-3. And then
- 1:34:17Speaker 2: the last one is Instagram, where I'm the most active,
- 1:34:21Speaker 2: hold underscore the line CLNC, where we talk about local
- 1:34:26Speaker 2: and state stuff. So happy to have everybody that listens,
- 1:34:29Speaker 2: write to us, let us know how we're doing. And,
- 1:34:31Speaker 2: you know, if you ever have any questions, just reach
- 1:34:33Speaker 2: out because we like to educate. And if we don't
- 1:34:36Speaker 2: know the answer, we can get your resources and make
- 1:34:39Speaker 2: sure people know what's going on in the community. So, yes,
- 1:34:41Speaker 2: thank you.
- 1:34:41Speaker 3: 100%. And for people that haven't already checked it out,
- 1:34:46Speaker 3: go check out the sternal rub on Spotify or rumble.
- 1:34:50Speaker 3: Make sure you follow that because they on fire, ladies
- 1:34:54Speaker 3: and gentlemen, golf clap. Thank you for branching to that.
- 1:34:59Speaker 3: So for me and for the beautiful, talented, and always
- 1:35:04Speaker 3: lovely nurse, Nicole, thanks for tuning in ladies and gentlemen,
- 1:35:09Speaker 3: and we will see you next time. Have a great one.